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1. Introduction 
Over the years, kidney transplants have faced problems of failure, months or years after 
having been carried out.  Chronic allograft nephropathy, abbreviated CAN is the major cause of 
this failure.  It can happen months to years after the transplant. This problem is characterized by 
slow decline in the working of the kidney and many a times go together with high blood 
pressure.  CAN is diagnosed by examination of tissue (kidney biopsy).  The histopathology is 
characterized by interstitial fibrosis, tubular atrophy, fibrotic intimal thickening of arteries and 
glomerulosclerosis. To test for the presence of the chronic allograft nephropathy, examination of 
tissues such as those from the kidney is done (Cacabelos et al, 2013, P.241).  
Cardiovascular morbidity and mortality are the most important reasons affecting patient 
survival after kidney transplantation (Kasiske BL., 1988).  Because CAN pathogenesis shares 
some similarities with the atherogenesis (Ross R. 1999), it has been hypothesized that some gene 
variants that may play a role in the pathogenesis of atherosclerosis, may also affect kidney graft 
survival (Suthanthiran M., 2000).  Hyperhomocysteinemia is an established, independent risk 
factor for vascular disease morbidity and mortality.  Identification of risk factors, such as 
hyperhomocysteinemia, is crucial for a better understanding of the events that lead to 
degenerative processes in the vascular system and for a correct understanding of the potential 
role of methylene-tetrahydrofolate reductase enzymes (MTHFR) to help in the treatment of 
vascular disease observed in chronic allograft nephropathy CAN).  Total blood levels of 
homocysteine (tHcy) have been shown to depend on both environmental and genetic factors 
(Cortese C, Motti C., 2001).  Elevated tHcy levels are frequently observed in patients with renal 
failure and after kidney transplantation.  The methylenetetrahydrofolate gene, MTHFR, is a form 
of a gene that is used as a guide in making the methylenetetrahydrofolate reductase which plays a 
role in processing amino acids which are the building blocks of proteins, through chemical 
reactions, to change the amino acids into more useful compounds.  Increased levels of 
homocysteine and the danger of cardiovascular diseases, mostly in people with kidney problems, 
is a problem associated to mutation in the human methylenetetrahydrofolate gene. 
In this paper, the effect and the influence of Methylemetetrahydrofolate is being reviewed, 
in that it causes gradual kidney dysfunction.   Methylemetetrahydrofolate reductase is regarded 
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as a primary and key enzyme for intracellular folate homeostasis and metabolism which causes 
an irreversible reaction by catalyzing the conversion of the molecule 5, 10-
methylenetetrahydrofolate to molecule 5-metyltetrahydrofolate which is a co-substrate for 
homocysteine remethylatiom to methionine.  Increased levels of homocysteine are said to be 
linked to mutation in the Methylenetetrahydrofolate gene that is found in the human 
chromosome 1p36.3.  There are two non-synonymous and single nucleotides in the 
methylenetetrafolate gene that in terms of functioning alter the protein product C677 found in 
Exon 4 into a reduced thermo labile compound or variant which is decreased in stability and its 
specificity in the way it reacts and is related to reduce methylenetetrahydrofolate reductase.  
There is another compound, A1298 that is normally found in Exon 7 and that helps in reducing 
methylenetetrahydrofolate reductase activity.  The polymorphisms highlighted above have 
recently been associated with a number of diseases such as defects in neural tubes, malignancies, 
vascular diseases, and cardiovascular diseases. 
Hyperhomocysteinemia has been discovered as a problem suffered by patients of kidney 
disease, more particularly those with end stage renal disease on dialysis, and it is thus said to 
play a role in their increased cardiovascular disease peril.  According to Cacabelos et al (2013, 
p.321) when combined with fibrinogen as risk factors, homocysteine may explain almost up to 
40% of the attributable mortality as far as chronic kidney disease is concerned. 
Methylenetetrahydrofolate dehydrogenase 1 and methylenehydrofolate reductase 5 10 are the 
two important folate metabolizing enzymes involved in the folate metabolic pathway.  The 
polymorphisms, MTHFR and the MTHFD are suspected to be associated with congenital heart 
disease susceptibility (Garre & Hernández p 13).  A number of mutations in the MTHFR gene 
are said to have been found in people with homocystinuria which can be described as a disorder 
that renders the body unable to process certain compound in amino acids properly (Fung et al, 
2012 p.241).  The effect of most of this mutation is that they change single amino acids in MTHF 
reductase.  These changes in turn impair the functioning of the enzyme and may eventually cause 
the enzyme to be inactivated.  Sometimes, a different form of the mutations may cause 
production of a too small and non-functioning type of the enzyme.  Normally, without the MTHF 
reductase playing its role, homocysteine cannot be converted to methionine.  Due to this reason, 
the amount of methionine is reduced, as homocysteine accumulates in the blood streams.  Excess 
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homocysteine is excreted through urine (Cacabelos et al, 2013 p.343).  Research has not yet 
discovered how changing levels of homocysteine and methionine cause different health problems 
affecting numerous parts of the body of the people with homocystinuria. This study aimed at 
performing a meta-analysis for the variant MTHF reductase rs1801131 in chronic allograft 
nephropathy and to determine its role in the event rate for chronic allograft nephropathy. 
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2. Literature review 
The MTHFR gene mainly provides guidelines for making an enzyme called 
methylenetetrahydrofolate reductase.  This enzyme plays a major function in processing amino 
acids, which are the building blocks of proteins.  MTHFR reductase is essential for chemical 
reactions involving various forms of the vitamin B9 (Currie et al, 2007, p.50).  This enzyme 
converts a molecule called 5, 10-MTHFR to a molecule called 5-MTHFR.  The reaction is 
essential for the multistep process that breaks amino acid homocysteine into another amino acid 
and methionine.  The proteins and other important compounds are made from methionine.  
About 40 mutations in the MTHFR gene have been discovered in people who have 
homocystinuria, a disorder that makes the body unable to process certain amino acids properly in 
the body.  These changes occurring in the body impair the function of the enzyme, and some 
other causes that make the enzyme inactivated in the body.  Other mutations occurring lead to 
the production of an abnormally non-functional version of the enzyme (Cacabelos et al, 2013, 
p.45).  Without functional MTHFR reductase, homocysteine is unable to be converted to 
methionine.  Homocysteine builds up in the bloodstream and the amount of methionine is 
reduced in the body.  The excess homocysteine is excreted in urine.  Although researchers have 
conducted some research but they have not yet determined how altered levels of homocysteine 
and methionine lead to some health problems affecting the bodies of the people. 
There are some variations in the MTHFR gene which have been associated with an 
increased risk of neural tubes defects, a group of defects that occur mainly during the 
development of the spinal cord and brain.  There are most well-studied polymorphisms related to 
neural tube defects changes a single DNA which is the building block in the MTHFR gene.  It 
replaces the nucleotide cytosine with the nucleotide thymine at position 677.  This common 
variant results in a form of MTHFR reductase that has reduced activity at higher levels of 
temperatures.   
Hyperhomocysteinemia is mainly associated with the increased venous thrombosis and 
cardiovascular disease (CVD).  Mutations which are carried in the human MTHFR gene have 
been associated with increased homocysteine levels and involved risks of CVD including people 
who are suffering from kidney disease.  Previous studies that have been carried out, have 
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indicated that this gene is associated with some morbid conditions including cardiovascular and 
cerebrovascular disease.  This is the first study that evaluates two common polymorphisms 
within the gene and also associates them with those coming from iothalamate.  Few studies have 
evaluated MTHFR polymorphisms which are associated with renal diseases.  Additionally, 
MTHFR A1298C was associated with UPCR as one of the potential confounder to the 
association, together with GFR decline over time.  Also proteinuria is an important risk factor 
affecting kidney disease progression (Jamison et al, 2009, p.738).  Therefore, polymorphisms 
from the associated gene, appear with homocysteine levels and have been associated with 
cardiovascular risk factors which include hypertension and renal function, which are responsible 
for causing these conditions to people. 
Elevation of the homocysteine levels could be brought about by either genetic or dietary 
factors.  In a study that was conducted on an Indian population, the majority of the population 
were found to have a lower level of vitamin B12.  This is mainly due to their dependence on a 
vegetarian diet which is one of the critical factors that leads to hyperhomocysteinemia.  
Therefore, polymorphisms in those genes that are found to be responsible for the metabolism of 
homocysteine, have been considered to have a greater influence when it comes to 
hyperhomocysteinemia in the Indian population.  For such reasons, effects of both 
methylenetrahydrofolate reductase (MTHFR) polymorphism and diet are significantly associated 
with high homocysteine levels (ACTON, 2012, p.21). 
Many publications have established statistically significant correlation between tacrolimus 
and Single Nucleotide Polymorphisms (SNP) (HARZALLAH, 2011, p.56).  Some working 
groups, researchers and consortia have even recommended guidelines for initial doze-adjustment 
with the SNP but are always being followed by TDM. 
Over the last decades, there has been unprecedented advancement in assessing the diversity 
of human diversity across the major human being population in development of the deep 
sequencing and high throughput genotyping technologies similar to the advancement of the scale 
maps of the population including international Hap Map project (ACTON, 2012, p.  52).  Such 
tools have been greatly utilized in deeply characterizing the architecture of the genotypes of rare 
and common diseases and brought about some other conditions such as adverse events and 
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severe drug effects.  However, up to date, the organ transplantation field has not yet benefited in 
any way from these advancements.  Whereas more than a thousand studies on organ rejection 
have already been published, there tend to be mostly candidate based and they suffer from the 
many pitfalls of genetic association.  These pitfalls include: lack of the required sample size, 
failure to include covariates like ethnicity, retrospective study designs, improper statistical 
correlation and replication especially in cases where multiple hypotheses are involved (ACTON, 
2012, p.  57). 
According to ENVER et al (2012, p.  12), the MTHFR C677T polymorphism brings about 
amino-acid alterations from alanine to valine making the enzymes to become half-deceased and 
thermo labile.  However, the prevalence varies among populations globally.  Therapeutic drug 
monitoring (TDM) acts as an indispensable and essential instrument for the dosing of calcineurin 
inhibitor and in the reduction of pharmacokinetic variability component via controlling the 
concentrations of the drug in blood.  However, this is possible only after the administration of 
drugs and patient compliance and achievement of a steady state.  This implies that some 
complementary strategies are required.  If the genetic variants are characterized, they can help in 
establishing effective doses which will minimize adverse reactions (ACTON, 2012, p.  33). 
Chronic Allograft Dysfunction is a very common outcome in transplantation of kidneys 
(LIU, 2001, p.17).  However, its pathogenesis has been unclear.  Its natural history has been 
explained to be as a result of an earlier of tubulointerstitial injury initiation that eventually makes 
interstitial fibrosis and tubular atrophy to become worse.  Earlier phases of chronic allograft 
dysfunction may occur within the three months after the transplant.  It is an irreversible damage 
that may lead to the declining of the kidney function as well as allograft failure.  Nevertheless, 
the rate at which the functioning of the kidney declines as well as the development of the failure 
of the allograft may vary in different CGD recipients.  Therefore, there exists a need for a further 
characterization of chronic allograft dysfunction phenotype to provide a better understanding of 
those phenotypes which will cause rapid development of allograft failure.  
Methylenetetrahydrofolate reductase (MTHFR) remains a very critical enzyme in the folate 
metabolism.  It is required in DNA repair, DNA methylation as well as DNA synthesis.  
Additionally, it has also remained a potential risk factor for neural tube defects.  Association of 
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C677T polymorphism in MTHFR gene and susceptibility to neural tube defects has already been 
widely established although the findings are still inconclusive (LIU, 2001, p.19). 
Methylenetetrahydrofolate reductase (MTHFR) is a crucial enzyme for metabolism of 
folate in humans and it is coded by the gene MTHFR.  This research has studied the assessment 
of association between polymorphism of MTHFR C677T and congenital heart defects risks 
while its findings were not consistent (D'Alessandro & Mital, 2013, p.398).  The congenital heart 
disease (CHD) is the type of birth defect which is common.  Polymorphism in metabolism of 
folate is suspected to be associated the increased risks of congenital heart disease although it is 
not clear.   
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3. The kidney and MTHFR genetic variation 
Vascular disease in renal transplant patients has been suggested to have a similar 
pathophysiology as vascular aging and atherosclerotic processes. MTHFR polymorphism has 
been evaluated by certain studies as associated with renal disease.  In renal failure, association of 
CVD and MTHFR polymorphisms has shown mixed findings.  Two universal genetic mutations 
were studied, A1298C and C677T, and were both shown to decrease the enzyme activity of 
MTHFR.  Increased levels of plasma homocysteine are associated with the polymorphism of 
C677T itself and in combination with the mutation of A1298C, as these levels of elevated 
homocysteine and polymorphism have been associated with morbidity and mortality of CVD.  
As it was hypothesized, that pathophysiologic mechanism might be mediated via levels of 
elevated homocysteine (Bosó et al, 2013 p.483).  Effective lowering of the levels of 
homocysteine with combination of treatment of vitamin like folate, B6 and B12 have not yet 
shown to decrease mortality in patients of renal failure who bear the burden of this disease, to be 
modified successfully.  Moreover, it is suggested that homocysteine may be vascular disease 
maker rather than causative agent (Tayeb et al, 2015, p.89).  C677T polymorphism has been 
reported to be 5-MTHF marker, circulating metabolite of folic acid which participates in the 
metabolism of homocysteine that seems to be the main controller of endothelial nitric oxide 
coupling synthase and nitric oxide available in the human vessels.  This may then motivate 
oxygen free-radical formation, which contributes to vascular oxidative stress, causing alteration 
in thrombogenicity and endothelial function and ultimately leading to atherothrombosis (Bosó et 
al, 2013, p.486).  Therefore, plasma homocysteine which is associated with CVD and 
cerebrovascular might be an indirect 5-MTHF marker other than primary endothelial function 
regulator.  Consistent with the hypothesis are the CVD and CKD mortality rates.  It is not clear 
whether the Polymorphism of MTHFR A1298C also increases levels of homocysteine.  It is not 
easy to evaluate levels of plasma homocysteine as they were defined at the AASK start trial and 
not available in the VAHC. 
Hyperhomocysteinemia is highly associated with rise of cardiovascular disease (CVD) and 
venous thrombosis (D'Alessandro & Mital, 2013, p.403).  Mutations in the human MTHFR 
reductase gene have been associated with rise in the levels of homocysteine and risks of 
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cardiovascular disease in certain populations with inclusion of those having kidney disease.  
Therefore, MTHFR-coding polymorphism is associated with renal decline at A1298C in African-
Americans having hypertensive nephrosclerosis, it is assisted by cohort having primary 
hypertension of care diagnosis. 
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4. Research Questions 
 What is MTHFR? 
 What is the normal function of MTHFR? 
 How are changes in MTHFR related to CAN? 
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5. Data Collection Methods 
5.1. Patients and Study Design 
Donors and their respective recipients who underwent surgery were included in study.  All 
recipients had under gone renal transplantation at least 12 months prior the investigations.  
Patients having biopsy proven subclinical acute rejection were not included in the studies.  
Plasma homocysteine concentrations were measured by liquid chromatography-tandem mass 
spectrometry and MTHFR polymorphisms were investigated by the PCR-RFLP technique.  After 
surgery, immunosuppression regiment was based in tacrolimus.  After transplantation, patients 
were followed up for the first two weeks for pharmacokinetic data, then again for 18 months for 
clinical data.  Clinical data, analytical data and length of stay in hospital after transplant were 
obtained from hospital records.  Genetic data and other additional information were obtained 
from study population with no disturbance to patient management and were handled in line with 
regulations in data registration, preservation and use of patient privacy. 
 
5.2. Measurement of tacrolimus concentrations and baseline immunosuppression 
The immunosuppression regimen was composed of corticosteroids, tacrolimus, 
mycophenolate and mofetil.  Treatment was started orally, 24 hours after surgery if there were no 
complications.  Patients received tacrolimus (orally) as a primary immunosuppression drug at 
initial doses of 0.1-0.2 mg/kg/day, subdivided to two doses.  Tracolimus dose was then 
individualized by TDM so as to maintain target blood through concentration 10-15 ng/mL.  After 
this, Tacrolimus blood samples were measured in blood samples obtained before tacrolimus dose 
administration in the morning.  Through clinical chemistry, a system of a minimum of four 
samples per patient was obtained. 
 
5.3. Genotyping 
From EDTA-anti-coagulated blood of transplanted recipients and donor, genotypic DNA 
was removed from 200 ul of blood.  DNA was extracted using a commercial kit which was based 
on centrifugation in micro-columns.  Quantification was then done using a spectrophotometer.  
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So as to determine purity and concentration, DNA was stored until use at -20 degrees C.  Genetic 
analysis program was then used to genotype the samples.  34 SNPs in 16 different genes was 
analyzed. 
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6. Statistical analysis 
Statistical calculations and analyses were performed by use of SPSS software and prism.  
Categorical variables obtained were then expressed as percentage.  Variables which were 
continuous were expressed as mean and median or interquartile range depending on the result on 
Kolmogorow-Smirnoff or Shapiro-Wilk normality test, depending on the sample size.  
Associations between categorical variables or genotypes were assed using a chi-square test.  For 
continuous variables Mann-Whitney U test was performed to compare groups and Kruskal-
Wallis test to compare several groups was used. 
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7. Results 
The following articles are used in meta-analysis of the topic of interest. They are coded to 
provide ease of developing tables. 
1. Association of methylenetetrahydrofolatereductase T677 allele with early development of 
chronic allograft nephropathy (Viklický et al., 2004). Coded study 1. 
2. Hyperhomocysteinemia and MTHFR C677T and A1298C polymorphisms are associated 
with chronic allograft nephropathy in renal transplant recipients (Pavarino-Bertelli et al., 
2004). Coded study 2. 
3. Polymorphism of the methynetetrahydrofolate reductase C677T gene with allograft 
nephropathy in renal tranplants recipients. Coded study 3. 
From these sources, the tables provided below are developed. 
Name of  
article 
Author’s name Publication 
year 
Type of 
observation 
study 
No. of 
Cohorts/cases 
No. of 
controls 
Study 1 Viklický et al. 2004 Cohort-control 92 365 
Study 2 Pavarino-Bertelli et al. 2004 Cross-
sectional 
53 57 
Study 3 Azapira N et al. Unknown  Unknown Unknown Unknown 
Table 1 Presentation of articles 
Name of  
article 
95% confidence interval (CI)  Odds ratio (OR) p-value 
Study 1 1.11 to 13.8 3.91 0.02 
Study 2 1.26 to 6.98 2.97 0.005 
Table 2 Analysis of articles 
Note: study 3 has not been included in table 2 since the article could not be retrieved (not 
available online).  Therefore, meta-analysis could not be properly carried out due to lack of 
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sufficient data to analyze.  However, even without a proper population of data, as only two 
articles were available, there is strong evidence that rs1801131 is closely linked with CAN. 
Genomic DNA obtained from renal transplant recipients and donors was genotyped.  It was 
then noted that the allele frequencies seen were consisted with those described in the SNP 
PubMed Database for the Caucasian population.  No associations between patients’ 
characteristics and SNPs studied were found. 
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8. Discussion 
Upon reviewing our results, we see that our research indicates that the coding of 
polymorphism at A1298C for MTHFR is somehow associated with renal decline.  In spite of 
polymorphisms from this gene that are said to appear and be associated or linked with 
homocysteine levels, and additionally linked with cardiovascular risk factors that include a high 
tension and also renal function. The factors that contribute to these huge conditions are changes 
in MTHFR gene and environmental factors.   
By examining the articles we analyzed, we conclude that the p-values from the two 
articles are less than 0.05 and OR are between 2.97 and 3.98. Therefore, the hypothesis is not 
rejected. So a deduction can be made that variant-MTHFR-rs1801131 is linked to chronic-
allograft-nephropathy. 
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9. Recommendation 
More research needs to be done about proteinuria, since it is an important factor of risk for 
kidney disease progression that may provide a link to the genotype. We recognized the study of 
polymorphisms in MTHFR gene as potential risk factors for a range of well-known conditions 
that include; stroke, heart disease, high blood pressure during pregnancy, eye disorder, certain 
types of cancer, high blood pressure, psychiatric disorders and cleft lip and palate.  Thus it 
remains unclear on what occurs during MTHFR gene play in these disorders, but a large number 
of environmental and genetic factors, which remain unknown, may likely facilitate the 
development of risk for most common, complex conditions. 
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